Please assess the completion status of the following clinical trial:

Trial Title: Varenicline and Nicotine Interactions in Humans (VA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male smokers, aged 18 to 55 years~* History of smoking daily for the past 12 months, at least 15 cigarettes daily~* Carbon Monoxide (Alveolar) level \> 10ppm~* For women: not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods~Exclusion Criteria:~* History of heart disease, renal or hepatic diseases~* other medical conditions that the physician investigator deems as contraindicated for the subject to be in the study~* Regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics)~* recent psychiatric diagnosis and treatment for Axis I disorders including~* major depression, bipolar affective disorder,~* schizophrenia and panic disorder within the past year~* Current dependence on alcohol~* drugs or treatments for drug~* alcohol addiction within the past 5 years~* Allergy to varenicline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo First, varenicline, + IV Nic (Type: EXPERIMENTAL): Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
- Varenicline first, placebo, + IV Nic (Type: EXPERIMENTAL): Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).